Renal damage associated with proteinuria

Kidney International, Supplement

Volumn 62, Issue 82, 2002, Pages

  Praga, Manuel ^a   Morales, Enrique ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Interstitial cellular infiltrates; Progressive renal disease; Tubulointerstitial fibrosis

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; VASOACTIVE AGENT; VERAPAMIL;

BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; GLOMERULUS; HUMAN; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; OBESITY; PRIORITY JOURNAL; PROTEIN INTAKE; PROTEIN RESTRICTION; PROTEINURIA; SODIUM RESTRICTION; WEIGHT REDUCTION; ANIMAL; DISEASE COURSE; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; REVIEW; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; KIDNEY FAILURE; NEPHRITIS, INTERSTITIAL; PROTEINURIA; TREATMENT OUTCOME;

EID: 0036435819     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.62.s82.9.x     Document Type: Conference Paper

References (36)

1. Ruggenenti P, Perna A, Mosconi L, et al: Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int 53:1209-1216, 1998
2. Peterson JC, Adler S, Burkart JM, et al: Blood pressure control, proteinuria, and the progression of renal disease: The Modification in Diet in Renal Disease Study. Ann Intern Med 123:754-762, 1995
3. Praga M, Hernández E, Montoyo C, et al: Long-term beneficial effects of ACE inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 20:240-248, 1992
4. Gansevoort R, De Zeeuw D, De Jong PE: Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal diseases. Am J Kidney Dis 22:202-206, 1993
5. Jafar TH, Stark PC, Schmid CH, et al: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal diseases. Kidney Int 60:1131-1140, 2001
6. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 339:1448-1456, 1998
7. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 51:2-15, 1997
8. Brunskill NJ: Mechanisms of albumin uptake by proximal tubular cells. Am J Kidney Dis 37 (Suppl 2):S17-S20, 2001
9. Burton CJ, Harper SJ, Bailey E, et al: Turnover of human tubular cells exposed to proteins in vivo and in vitro. Kidney Int 59:507-514, 2001
10. Eddy A: Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7:2495-2508, 1996
11. Abbate M, Zoja C, Corna D, et al: In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 9:1213-1224, 1998
12. Eddy A. Role of cellular infiltrates in response to proteinuria. Am J Kidney Dis 37 (Suppl2): S25-S29, 2001
13. Zoja Z, Donadelli R, Colleoni S, et al: Protein overload stimulates RANTES production by proximal tubular cells depending on NF-κB activation. Kidney Int 53:1608-1615, 1998
14. Guijarro C, Egido J: Transcription factor-κB (NF-κB) and renal disease. Kidney Int 59:415-424, 2001
15. Rangan G, Wang Y, Tay Y, Harris DCH: Inhibition of nuclear factor-κB activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int 56:118-134, 1999
16. Morrisey JJ, Klahr S: Enalapril decreases nuclear factor κB activation in the kidney with ureteral obstruction. Kidney Int 52:926-933, 1997
17. Taal MW, Brenner BM: Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int 57:1803-1817, 2000
18. Taguma Y, Kitamoto Y, Futaki G, et al: Effect of captopril in heavy proteinuria in azotemic diabetes. N Engl J Med 313:1617-1620, 1985
19. Heeg JE, De Jong Pe, Van Der Hem GK, et al: Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 36:272-279, 1989
20. Lewis EJ, Hunsicker L, Bain RP, Rhode RP, for the Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
21. Maschio G, Alberti D, Janin G et al: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334: 939-945, 1996
22. The Gisen Group: Randomised placebo-controlled trial of effect of ramipril on declining in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
23. Jafar TH, Schmid CH, Landa M, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73-87, 2001
24. Lewis EJ, Hunsicker LG, Clarke WR, et al, for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbersartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
25. Brenner BM, Cooper ME, De Zeeuw D, et al: for the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
26. Parving HH, Lehnert H, Bröchner-Mortensen J, et al: The effect of irbersartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
27. Laverman G, Henning RH, De Jong Pe, et al: Optimal antiprotein-uric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 38:1381-1384, 2001
28. Sharma K, eltayeb BO, McGowan TA, et al: Captopril-induced reduction of serum levels of TGF-β correlates with long-term reno-protection in insulin-dependent diabetic patients. Am J Kidney Dis 34:818-823, 1999
29. Ruilope LM, Casal MC, Praga M, et al: Additive antiproteinuric effect of converting enzyme inhibition and a low protein intake. J Am Soc Nephrol 3:1307-1311, 1992
30. Buter H, Hemmelder MH, Navis GJ, et al: Blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlothiazide. Nephrol Dial Transplant 13:1682-1685, 1988
31. Praga M, Hernández E, Morales E, et al: Clinical features and long-term outcome of obesity-associated focal segmental glomeru-losclerosis. Nephrol Dial Transplant 16:1790-1798, 2001
32. Russo D, Pisani A, Balletta MM, et al: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33:851-856, 1999
33. Agarwal R: Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 59:2282-2289, 2001
34. Bakris GL: Barnhillbw, Stadler R. Treatment of arterial hypertension in diabetic man: Importance of therapeutic selection. Kidney Int 41:898-906, 1992
35. Hemmelder MH, De Zeeuw D, De Jong Pe: Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease. Nephrol Dial Transplant 14:98-104, 1999
36. Wang JL, Cheng HF, Shappell S, Harris RC: A selective cycloox-ygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 57:2334-2342, 2000